The efficacy and safety of low-dose Apatinib in the management of stage IV luminal-type breast cancer: a case report and literature review

Lv, Xingxing; Chen, Juan; Yi, Tingwu; Lü, Hong; Liu, Juan; Yu, Danfei

doi:10.1097/cad.0000000000001102

Cited by 4 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the high malignancy of gallbladder cancer, chemotherapy can directly kill tumor cells [ 6 , 7 ]. Gemcitabine, oxaliplatin, and apatinib all have significant effects on the treatment of tumors [ 8 , 9 ]. Gemcitabine has a strong broad-spectrum antitumor activity and a unique mechanism of action and is widely used in the treatment of malignant tumors in clinical practice; oxaliplatin has the advantage of significant effects and few adverse effects; and apatinib is able to antagonize vascular endothelial growth factor receptor 2 (VEGFR-2) and can effectively promote apoptosis of tumor cells.…”

Section: Introductionmentioning

confidence: 99%

Effects of Gemcitabine and Oxaliplatin Combined with Apatinib on Immune Function and Levels of SIL-2R and sicAM-1 in Patients with Gallbladder Cancer

Liu

et al. 2022

Computational Intelligence and Neuroscience

View full text Add to dashboard Cite

Objective. The aim of this study was to determine how gemcitabine, oxaliplatin combination, and apatinib affect immune function and SIL-2R and sicAM-1 levels in patients with gallbladder cancer. Methods. Retrospective analysis of 116 patients with gallbladder cancer treated at our institution between February 2019 and February 2021. The patients were randomly divided into control and study groups, with 58 patients in each group. The study group received the combination of apatinib and the control group received gemcitabine and oxaliplatin. Immune function, serum tumor markers, short-term efficacy, survival measures, and incidence of adverse events were monitored and compared between the two groups. Results. CD3+, CD4+, CD4+/CD8+, and NK levels were significantly higher in both groups after treatment, while CD8+ levels were significantly lower; levels of sicAM-1, sicAM-1 (VEGF), and CEA were greatly reduced in both groups after treatment; there were significant differences between the study and control groups in terms of rr46.55% and DCR84.48%; at one year after treatment, the survival rate in the study group increased from 67.24% in the control group to 79.31%, with an increase in both PFs and 0S. Compared with the control group, the incidence of hypertension and myelosuppression, neutropenia, proteinuria, and hand-foot syndrome were lower in the study group ( P < 0.05 ). All differences were statistically significant. Conclusion. In the treatment of gallbladder cancer, the use of gemcitabine and oxaliplatin combined with apatinib can effectively control the progression of patients’ disease.

show abstract

Section: Introductionmentioning

confidence: 99%

Effects of Gemcitabine and Oxaliplatin Combined with Apatinib on Immune Function and Levels of SIL-2R and sicAM-1 in Patients with Gallbladder Cancer

Liu

et al. 2022

Computational Intelligence and Neuroscience

View full text Add to dashboard Cite

show abstract

“…Recent studies have demonstrated the antitumor activity of apatinib in several solid tumors (Zhang et al, 2022b;Xiang et al, 2022;Zhu et al, 2022). Tumor angiogenesis plays an important role in tumor development and metastasis, and antiangiogenic drugs may improve the efficacy of conventional chemotherapy in the treatment of breast cancer (Liu et al, 2021;Lv et al, 2021). Apatinib inactivates the NF-κB signaling pathway, which makes TNBC cells sensitive to anthracyclines in vitro and in vivo.…”

Section: Discussionmentioning

confidence: 99%

Case report: Apatinib combined with neoadjuvant therapy for primary squamous cell carcinoma of the breast: a case report

Gao

Liao

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Primary squamous cell carcinoma of the breast is a rare subtype of carcinoma of chemosis for which there is no effective chemotherapy regimen. Breast squamous cell carcinoma is usually “triple negative”, with poor chemotherapy effects and poor prognosis. Here, we report a successful case of primary breast squamous cell carcinoma treated with apatinib. The patient was treated with 2 cycles of apatinib. The efficacy was evaluated as partial remission, and a sublesion of approximately 4 cm fell off.

show abstract

“…Consequently, it has been reported that apatinib could be an effective option for the HER2-positive tumors. Luckily, a female patient with HR-positive and HER2-negative stage of breast cancer showed significant improvement in the symptoms upon low dose of apatinib [ 20 ]. However, the details about other additional treatments or clinical history were not provided; hence, efficacy of the apatinib in this case is doubtful.…”

Section: Discussionmentioning

confidence: 99%

Apatinib and Ginsenoside-Rb1 Synergetically Control the Growth of Hypopharyngeal Carcinoma Cells

Pan

2022

Disease Markers

View full text Add to dashboard Cite

Background. Apatinib is an anticancer drug known to inhibit the vascular endothelial growth factor receptor-2 (VEGFR-2) through regulating tyrosine kinases. Drug resistance and reduced activity in various cancers is the matter of great concern; thus, researchers opt to use combination of the two or more drugs. So far, its gynergetic anticancer role with a traditional Chinese drug Ginsenoside-Rb1 (G-Rb1) has not been studied in cancers including hypopharyngeal carcinoma. Objective. The current study is aimed at investigating the anticancer synergetic effects of G-Rb1 and apatinib in hypopharyngeal carcinoma. Methods. The synergetic effects of both drugs on cell proliferation, wound healing and cell migration, and cell apoptosis were studied in hypopharyngeal carcinoma cells. Furthermore, the xenograft rat model was generated, and tumor inhibition was monitored after treating rats with both drugs as mono- and combination therapy. In addition, protein expression and localization were performed by western blotting and immunofluorescent staining, respectively. Results. The analyses of the data showed that combination therapy of apatinib and G-Rb1 significantly inhibited the proliferation, migration, and wound healing capability of hypopharyngeal carcinoma cells. Moreover, the glycolysis rate of the cells in the combination therapy (apatinib and G-Rb1) group was significantly decreased as compared to that in the monotherapy group or no treatment group, suggesting that the glycolysis inhibition led to the inhibition of tumor growth. Moreover, the combination therapy on xenograft rats dramatically reduced the tumor size. Furthermore, combination therapy also exhibited an increased count of CD3+ and CD4+ T cells, as well as the ratio between CD4+ and CD8+ T cells. Conclusion. Interestingly, a combination of apatinib and G-Rb1 induced more tumor cell apoptosis and reduced cell proliferation than the individual drug treatment and promote antitumor immunity by enhancing immunomodulatory molecules. Thus, we believe that this study could serve as a valuable platform to assess the synergetic anticancer effects of the herbal as well as synthetic medicines.

show abstract

The efficacy and safety of low-dose Apatinib in the management of stage IV luminal-type breast cancer: a case report and literature review

Cited by 4 publications

References 21 publications

Effects of Gemcitabine and Oxaliplatin Combined with Apatinib on Immune Function and Levels of SIL-2R and sicAM-1 in Patients with Gallbladder Cancer

Effects of Gemcitabine and Oxaliplatin Combined with Apatinib on Immune Function and Levels of SIL-2R and sicAM-1 in Patients with Gallbladder Cancer

Case report: Apatinib combined with neoadjuvant therapy for primary squamous cell carcinoma of the breast: a case report

Apatinib and Ginsenoside-Rb1 Synergetically Control the Growth of Hypopharyngeal Carcinoma Cells

Contact Info

Product

Resources

About